JME-001 phase II trial of first-line combination chemotherapy with cisplatin, pemetrexed, and nivolumab for unresectable malignant pleural mesothelioma

BACKGROUND: JME-001 is a phase II trial assessing the efficacy and safety of cisplatin, pemetrexed, and nivolumab as first-line therapy in malignant pleural mesothelioma (MPM). PATIENTS AND METHODS: Patients with untreated, unresectable MPM with an Eastern Cooperative Oncology Group (ECOG) performan...

Descripción completa

Detalles Bibliográficos
Autores principales: Miyamoto, Yosuke, Kozuki, Toshiyuki, Aoe, Keisuke, Wada, Sae, Harada, Daijiro, Yoshida, Michihiro, Sakurai, Jun, Hotta, Katsuyuki, Fujimoto, Nobukazu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8557301/
https://www.ncbi.nlm.nih.gov/pubmed/34711664
http://dx.doi.org/10.1136/jitc-2021-003288

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8557301/
https://www.ncbi.nlm.nih.gov/pubmed/34711664
http://dx.doi.org/10.1136/jitc-2021-003288

Ejemplares similares